Updated timetable regarding Calmark's LDH test for Covid-19 assessment

Report this content

Calmark Sweden AB announces today that the timetable for the development project related to the product COVID19-LDH has been updated. The CE marking of this POC test will take place one to two weeks later than previously disclosed.

"Verification and validation of COVID19-LDH is currently underway, as announced on 18 February. This phase is expected to be completed shortly after Easter”, comments Anna Söderlund, CEO. "After this, we expect to be able to quickly complete the transfer to production and CE mark the product."

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-03-2021 16:55 CET.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.  


Documents & Links